Managing the Complex and Differentiated Patient With Hemophilia: Managed Care Considerations in Diagnosis, Treatment Selection, and Unmet Needs

Program Description

Hemophilia is a rare, inherited bleeding disorder caused by a deficiency in clotting factor VIII or IX, affecting an estimated 33,000 people in the United States. Aside from potentially life-threatening bleeding episodes, hemophilia drives lifelong risk of joint damage, chronic pain, and diminished quality of life. For decades, factor replacement therapy has been the mainstay of treatment, but a wave of newer nonfactor therapies is reshaping the treatment landscape with novel mechanisms of action and potentially less frequent, subcutaneous dosing options that may improve medication use and quality of life. These advances increase the complexity of decision-making for managed care professionals, as they must weigh evolving clinical trial and real-world evidence, mechanism-specific monitoring needs, and treatment costs when designing formularies, prior authorization criteria, and utilization management strategies. Payers, pharmacy benefit managers, pharmacy directors, and Pharmacy and Therapeutics committee members are increasingly called on to translate this rapidly changing evidence base into coverage decisions that balance patient access with responsible resource allocation. This webinar will equip managed care professionals and pharmacists with an updated understanding of hemophilia pathophysiology, the mechanisms and evidence supporting nonfactor therapies, and practical strategies for building formularies and utilization management approaches that reflect current clinical guidance.

Target audience: Managed  Care Pharmacists
Type of activity: Application
Release date: September 28, 2026
Expiration date: December 19, 2026
Time to complete activity: 1 hour
Learner level: Foundational, Intermediate
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Ascertain the disease pathology in hemophilia, variability in disease presentation, and ongoing patient burden of disease
• Interpret clinical trial and real-world evidence for nonfactor therapies and their mechanisms of action compared with traditional factor replacement therapies
• Construct formularies and drug utilization management strategies that align with clinical trial evidence and support improved outcomes for patients with hemophilia

Accreditation Information

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This application-based activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-26-288-L01-P. The activity is available for CE credit through November 28, 2026.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Nisha Bhide, PharmD, has the following relevant financial relationship with an ineligible company to disclose: Stock: Employee of PBM: Senior Director of Formulary for a PBM (Judi Health)

Educational Disclaimer

CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]

Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms